These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 7734326

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Distal chromosome 17q loss in Barrett's esophageal and gastric cardia adenocarcinomas: implications for tumorigenesis.
    Petty EM, Kalikin LM, Orringer MB, Beer DG.
    Mol Carcinog; 1998 Aug; 22(4):222-8. PubMed ID: 9726814
    [Abstract] [Full Text] [Related]

  • 5. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
    Sanz-Ortega J, Hernández S, Saez MC, Sierra E, Sanz-Ortega G, Torres A, Balibrea JL, Sanz-Esponera J, Merino MJ.
    Hepatogastroenterology; 2003 Aug; 50(50):404-7. PubMed ID: 12749233
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.
    González MV, Artímez ML, Rodrigo L, López-Larrea C, Menéndez MJ, Alvarez V, Pérez R, Fresno MF, Pérez MJ, Sampedro A, Coto E.
    J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma.
    Suspiro A, Pereira AD, Afonso A, Albuquerque C, Chaves P, Soares J, Leitão CN.
    Am J Gastroenterol; 2003 Apr; 98(4):728-34. PubMed ID: 12738448
    [Abstract] [Full Text] [Related]

  • 10. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy.
    Blount PL, Galipeau PC, Sanchez CA, Neshat K, Levine DS, Yin J, Suzuki H, Abraham JM, Meltzer SJ, Reid BJ.
    Cancer Res; 1994 May 01; 54(9):2292-5. PubMed ID: 8162566
    [Abstract] [Full Text] [Related]

  • 11. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma.
    Blount PL, Ramel S, Raskind WH, Haggitt RC, Sanchez CA, Dean PJ, Rabinovitch PS, Reid BJ.
    Cancer Res; 1991 Oct 15; 51(20):5482-6. PubMed ID: 1680552
    [Abstract] [Full Text] [Related]

  • 12. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites.
    Dolan K, Garde J, Gosney J, Sissons M, Wright T, Kingsnorth AN, Walker SJ, Sutton R, Meltzer SJ, Field JK.
    Br J Cancer; 1998 Oct 15; 78(7):950-7. PubMed ID: 9764589
    [Abstract] [Full Text] [Related]

  • 13. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation.
    Wongsurawat VJ, Finley JC, Galipeau PC, Sanchez CA, Maley CC, Li X, Blount PL, Odze RD, Rabinovitch PS, Reid BJ.
    Cancer Epidemiol Biomarkers Prev; 2006 Mar 15; 15(3):509-16. PubMed ID: 16537709
    [Abstract] [Full Text] [Related]

  • 14. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas.
    Wong DJ, Barrett MT, Stöger R, Emond MJ, Reid BJ.
    Cancer Res; 1997 Jul 01; 57(13):2619-22. PubMed ID: 9205067
    [Abstract] [Full Text] [Related]

  • 15. Physical and transcript map of the minimally deleted region III on 17p implicated in the early development of Barrett's oesophageal adenocarcinoma.
    Dunn JR, Risk JM, Langan JE, Marlee D, Ellis A, Campbell F, Watson AJ, Field JK.
    Oncogene; 2003 Jun 26; 22(26):4134-42. PubMed ID: 12821948
    [Abstract] [Full Text] [Related]

  • 16. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
    Chao DL, Maley CC, Wu X, Farrow DC, Galipeau PC, Sanchez CA, Paulson TG, Rabinovitch PS, Reid BJ, Spitz MR, Vaughan TL.
    Cancer Epidemiol Biomarkers Prev; 2006 Oct 26; 15(10):1935-40. PubMed ID: 17035402
    [Abstract] [Full Text] [Related]

  • 17. The evolution of loss of heterozygosity on chromosome 17 during the progression to barrett's adenocarcinoma involves a unique combination of target sites in individual specimens.
    Dunn JR, Garde J, Dolan K, Gosney JR, Oates BC, Watson AJ, Fielding P, Field JK.
    Clin Cancer Res; 2000 Oct 26; 6(10):4033-42. PubMed ID: 11051253
    [Abstract] [Full Text] [Related]

  • 18. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M, Saure C, Pahl R, Schorr F, Rüschoff J, Alles JU, Heinmöller E.
    Pathol Res Pract; 2008 Oct 26; 204(5):285-94. PubMed ID: 18337019
    [Abstract] [Full Text] [Related]

  • 19. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas.
    Michael D, Beer DG, Wilke CW, Miller DE, Glover TW.
    Oncogene; 1997 Oct 02; 15(14):1653-9. PubMed ID: 9349498
    [Abstract] [Full Text] [Related]

  • 20. Genomic analysis of Barrett's esophagus after ablative therapy: persistence of genetic alterations at tumor suppressor loci.
    Hage M, Siersema PD, Vissers KJ, Dinjens WN, Steyerberg EW, Haringsma J, Kuipers EJ, van Dekken H.
    Int J Cancer; 2006 Jan 01; 118(1):155-60. PubMed ID: 16032707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.